Gilead Sciences | GILD - Ebitda

Prezzo Delle Azioni
130.40
Cambio Giornaliero
-3.24 -2.42%
Mensile
-5.68%
Annuale
26.39%
Q2 Previsione
127.61




Ebitda Cambiamento Data
AbbVie USD 3.52B 828M 2025-09
Agios Pharmaceuticals USD -115.49M 10.3M 2025-09
ALKERMES USD 100.31M 21.24M 2025-12
Alnylam Pharmaceuticals USD 145.22M 236.56M 2025-12
Amgen USD 5.14B 775M 2025-12
Biogen USD 573.2M 253.7M 2025-12
BioMarin Pharmaceutical USD -24.17M 18.91M 2025-12
Bristol-Myers Squibb USD 4.24B 967M 2025-09
Coherus Biosciences USD -43.33M 4.7M 2025-09
Eli Lilly USD 7.88B 378.1M 2025-09
Gilead Sciences USD 3.02B 1.01B 2025-12
GlaxoSmithKline GBP 3.36B 179M 2025-09
Glaxosmithkline GBP 4.75B 1.52B 2025-09
Incyte USD 414.5M 92.42M 2025-12
J&J USD 7.19B 2.32B 2025-12
Merck USD 8.39B 1.97B 2025-09
Moderna USD -790M 582M 2025-12
Neurocrine Biosciences USD 218.4M 28.3M 2025-12
Novartis USD 4.77B 1.11B 2025-12
Pfizer USD 6.08B 351M 2025-09
PTC Therapeutics USD -70.99M 91.62M 2025-12
Puma Biotechnology USD 729K 11.36M 2024-06
Regeneron Pharmaceuticals USD 1.92B 261.9M 2025-09
Sanofi EUR 3.31B 3.65B 2026-03
Sarepta Therapeutics USD -168.03M 294.45M 2025-09
United Therapeutics USD 379.5M 83.4M 2025-12
Vertex Pharmaceuticals USD 1.44B 100.4M 2025-09